Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Recent advances in β-thalassemia

Andreas Kulozik • 24 Apr 2022
The 2022 Tandem Meetings
Non-Malignant Thalassemia

Andreas E. Kulozik, MD, PhD, Hopp-Children’s Cancer Research Center (KiTZ), University of Heidelberg, Heidelberg, Germany, gives an overview of the latest advances in β-thalassemia, including developments in gene therapy and gene editing, as well as the introduction of new drugs such as luspatercept, which have been shown to improve hemoglobin levels and reduce transfusion requirements. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Andreas Kulozik

1:01
Management of patients with thalassemia who cannot undergo HSCT or gene therapy
Andreas Kulozik • 24 Apr 2022
1:35
The mechanism of action of hydroxyurea in SCD
Andreas Kulozik • 24 Apr 2022
2:13
The pathophysiology of β-thalassemia
Andreas Kulozik • 24 Apr 2022
1:48
Toxicity of beti-cel in transfusion-dependent β-thalassemia
Andreas Kulozik • 24 Apr 2022

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals